LEXINGTON, Mass., June 22, 2020 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, cell therapy, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, announced that it will make a scientific presentation
today on optimal anti-cancer combinations with Fc enhanced
anti-CTLA-4, AGEN1181, at the American Association for Cancer
Research (AACR) 2020 Virtual Annual Meeting.
"AGEN1181 is an Fc-engineered anti-CTLA-4 that has shown
exciting clinical activity in an early phase 1 clinical trial,
which was recently presented at ASCO," said Dr. Antoine Tanne, Lead Scientist, Agenus Immune
Biology Team. "Today, at AACR, we report that combinations
with AGEN1181 demonstrate curative responses in preclinical models
resistant to anti-PD-1. These data illustrate the potential
of combining allogeneic cell therapies with checkpoint antibodies,
such as AGEN1181, to deliver curative benefit in difficult to treat
settings."
Title: "Expanding the therapeutic potential of anti-PD-1 and
anti-CTLA-4 therapy with innovative Fc engineering and rationale
combinations for the treatment of solid tumors"
Presenter: Antoine J. Tanne. Ph.D
Abstract: 922 /
24
Session: Combination
Immunotherapies 1
Date/Time: June 22, 2020, 9am-6pm
Presentations will be available for on-demand viewing online
at
https://www.abstractsonline.com/pp8/#!/9045/sessions/@sessiontype=Virtual%20Symposium/1
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Forward-Looking Statements
This press release contains
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including
statements regarding the therapeutic potential of combining
allogeneic cell therapies with antibodies such as AGEN1181. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer
Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-cell-therapy-and-checkpoint-antibody-combinations-show-curative-preclinical-efficacy-at-aacr-2020-301081056.html
SOURCE Agenus Inc.